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Abstract 
Context: The incidence of low-risk prostate cancer (PCa) has increased as a 
consequence of prostate-specific antigen testing.  
Objective: In this collaborative review article, we examine recent literature regarding low-
risk PCa and the available prognostic and therapeutic options.  
Evidence acquisition: We performed a literature review of the Medline, Embase, and 
Web of Science databases. The search strategy included the terms: prostate cancer, low 
risk, active surveillance, focal therapy, radical prostatectomy, watchful waiting, biomarker, 
MRI, alone or in combination.  
Evidence synthesis: Prospective randomized trials have failed to show an impact of 
radical treatments on cancer-specific survival in low-risk PCa patients. Several series 
have reported the risk of adverse pathologic outcomes at radical prostatectomy (RP).  
However, it is not clear if these patients are at higher risk of death from PCa. Long term 
follow-up indicates the feasibility of active surveillance in low-risk PCa patients, although 
approximately 30% of men starting active surveillance undergo treatment within 5 years. 
Considering focal therapies, robust data investigating its impact on long-term survival 
outcomes are still required and therefore should be considered experimental. Magnetic 
resonance imaging and tissue biomarkers may help to predict clinically significant PCa in 
men initially diagnosed with low-risk disease.   
Conclusions: The incidence of low-risk PCa has increased in recent years. Only a small 
proportion of men with low-risk PCa progress to clinical symptoms, metastases or death 
and prospective trials have not shown a benefit for immediate radical treatments. Tissue 
biomarkers, magnetic resonance imaging, and ongoing surveillance may help to identify 
those men with low-risk PCa who harbor more clinically significant disease. 
Patient summary: Low-risk PCa is very common. Active surveillance has excellent long-
term results, while randomized trials have failed to show a beneficial impact of immediate 
radical treatments on survival. Biomarkers and magnetic resonance imaging may help to 
identify which men may benefit from early treatment. 
 
 
Introduction 
The incidence of prostate cancer (PCa) has increased over the past two decades 
due to the widespread use of prostate specific antigen (PSA) screening [1]. This trend is 
most marked in low-risk localized PCa[2], while a considerable reduction of metastatic 
PCa at diagnosis has been reported[3],[4],[5].  
A significant challenge is to differentiate PCa destined to cause clinical symptoms 
or metastases from more clinically indolent PCa that is highly unlikely to impact survival, 
even without immediate treatment. To this aim, several risk classifications have been 
proposed on the basis of clinical and pathological characteristics such as clinical stage, 
PSA and biopsy Gleason score. Several local active treatments have been proposed in 
this setting, such as radical prostatectomy (RP), external beam radiotherapy (EBRT) or 
active surveillance (AS). Although several different AS protocols have been proposed, it 
generally consists of monitoring with PSA, prostate exam, +/- MRI, and repeat prostate 
biopsies. It differs from watchful waiting, which is a passive approach where symptomatic 
progression prompts the subsequent use of palliative treatment. 
The aim of this review is to evaluate currently available literature about low-risk 
PCa and to provide a contemporary overview of diagnostic approaches and available 
management options.  
 
 
 
Evidence acquisition 
A literature review was performed in June 2016 using the Medline, Embase, and 
Web of Science databases. The search strategy included the terms “prostate cancer”, 
“low risk”, “active surveillance”, “focal therapy”, “radical prostatectomy”, “watchful waiting”, 
“biomarker”, “magnetic resonance imaging”, alone or in combination. The search was 
limited to the English literature. References cited in selected articles and in review articles 
retrieved in our search were also used to identify manuscripts that were not included in 
the initial search. The articles that provided the highest level of evidence were then 
evaluated. When existing, prospective studies were preferred to retrospective designs. A 
list of articles judged to be highly relevant by the first and senior authors was circulated 
among the coauthors and a final consensus was reached on the structure of the review 
and the articles included. The systematic review was performed in agreement with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines[6]. Figure 1   
 
Evidence synthesis 
Figure 1 shows a flow diagram of the selection process for this systematic review of the 
literature. Out a total of 723 articles screened, 189 were initially assessed for eligibility. 
Of these 121 were subsequently excluded and 26 were selected and included by authors. 
In total, 94 articles were selected and critically analyzed.  
 
 
Definition of low risk PCa 
Low-risk localized disease has generally been defined as clinical stage T1-T2, 
biopsy Gleason score ≤6 and PSA<10 ng/ml. Almost all risk classifications utilize these 
risk factors based on outcome data after whole-gland treatments (Table 1). D’Amico et 
al.[7] first proposed a risk group system based on data from 1,872 patients treated with 
radical prostatectomy (RP) or radiotherapy (RT) with or without androgen deprivation 
therapy. Groups were defined based on the incremental risk of developing biochemical 
recurrence. Consequently, the European Association of Urology (EAU)[8] and American 
Urological Association (AUA) adopted this risk scoring classification. The Radiation 
Therapy Oncology Group (RTOG) also proposed a system to predict overall and cancer-
specific mortality in PCa patients treated with radiation only[9]. These grouping systems 
were improved by continuous multivariate models of risk such as nomograms and 
integrating standard pathological variables such as number of biopsy cores involved and 
% of cores involved[10],[11]. Although these refinements better discriminate disease risk 
than the simpler operational definitions, their greatest utility is in those with intermediate 
and high-risk disease. 
The current NCCN guideline[12] implemented divided low-risk disease into two 
classes: very-low and low-risk groups. Although the definition of low-risk PCa disease is 
consistent with the previously described, the very-low risk population includes a subgroup 
of low-risk patients with the following characteristics: clinical stage T1c, Gleason score 
≤6, PSA<10 ng/ml, < 3 biopsy cores with cancer, ≤50% PCa involvement in any core and 
PSA density < 0,15 ng/ml/g, which is based on criteria proposed by Epstein[13] for 
determining the optimal biopsy findings associated with low-volume, low-grade cancer at 
RP. In a recent update of the Epstein criteria, unilateral cancer has replaced ≤50% PCa 
involvement in any core[14]. 
 
The new Grade Group grading system and its impact on low risk PCa 
Consensus conferences of 2005 and 2014 modified the Gleason grading system 
leading to the elimination of Gleason scores 2-5 and set a more restrictive definition of 
Gleason score 6[15],[16]. The major consequence of these changes is a more favorable 
prognosis of patients diagnosed with contemporary Gleason 6 compared to historical 
patients [17],[18]. Therefore, a new grading system composed of 5 grades where grade 
group 1 is equivalent to contemporary Gleason score 6 has been developed by Epstein 
and colleagues. Informing patients they have a potentially indolent-behaving cancer 
reflected in grade group 1  has the potential to permit more rational and less emotional 
decision-making[19],[20]. This system has been recently adopted by the WHO[21],[22], 
in the cancer protocol templates (CAP) and 8th revision of the TNM. 
 
Prospective trials evaluating the management of low-risk PCa 
The natural history of PCa and the impact of radical treatment on survival and 
functional outcomes have been investigated by several randomized trials[23],[24],[25]. Of 
these, only two analyzed outcomes of men with low-risk PCa (Table 2) [23],[24]. Wilt et 
al.[23] reported data from the Prostate Cancer Intervention versus Observation Trial 
(PIVOT) where 731 patients were randomly assigned between 1994 and 2002 to RP or 
observation with a median follow up of 10 years. Patients less than 75 years old were 
recruited from multiple centers and had clinical stage of T1-T2NxM0 and PSA < 50 ng/ml. 
At 12 years, cancer-specific mortality rates were 4.4% vs. 7.4% for patients treated with 
RP versus patients observed, respectively (p = 0.09). Considering 296 low-risk PCa 
patients, 148 were treated with RP and 148 were observed.  No differences were found 
considering survival expectations, where patients treated with RP or observation recorded 
both a 12-yrs CSM of 2.7% (p=0.5).  
 These results should be interpreted within the limitations of the study as the 
original power calculation was based on recruitment of 2000 cases, while it was 
subsequently adjusted for the recruitment of 740 men and results are therefore 
underpowered. Moreover, only 25% of all men had Gleason score of ≥7. Another 
limitation is represented by the fact that despite eligibility criteria included a 10-yr life 
expectancy and surgically curable disease, almost half of patients died of other causes 
before 10 yr and only half treated with surgery had an organ confined-disease.  
Bill-Axelson et al. [24] reported Scandinavian Prostate Cancer Group Study 
Number 4 (SPCG-4) where 695 men with localized PCa were randomly assigned to RP 
or observation. Patients were treated at 14 centers in Sweden, Finland and Iceland. 
Eligible criteria were: PSA<50 ng/ml, clinical stage ≤T2, negative bone scan, < 75 years 
of age with a life expectancy of more than 10 years and no other cancer. At 18 years, 
overall mortality rates were 56% vs. 69% for patients treated with RP vs watchful-waiting, 
respectively (relative risk [RR]: 0.71, confidence interval [CI]: 0.59-0.86, p<0.001). The 
number needed to treat to prevent one death at 18 years was 8. At 18 years, 17.7% died 
from prostate cancer from the RP group with 28.7% from the watchful waiting group (RR: 
0.56, CI: 0.41-0.77, p=0.001). Among the 249 low-risk PCa patients, a reduction of 15.6% 
in the risk of death from any cause and 10.6% in the risk of metastases was reported (p 
values: 0.002 and 0.006, respectively). In contrast, the reduction of 3.8% in the risk of 
dying for PCa was not significant (p=0.2). The aforementioned trials enrolled patients 
between 1994-2002 and 1989-1999. Several notable differences can be identified when 
compared to contemporary low-risk patients, such as: different biopsy techniques, 
modifications in Gleason scoring and differences in treatments. A minority of patients 
included in these trials had low-risk characteristics (36% and 40%), while contemporary 
patients diagnosed following PSA screening more commonly have low-risk features[1].  
Recently, the Prostate Testing for Cancer and Treatment (ProtecT) trial [25] 
presented 82,429 men between 50 to 69 years who received a PSA test between 1999 
and 2009. Overall 2,664 patients were diagnosed with localized PCa; of these, 1,643 
agreed to undergo randomization to active monitoring (545), surgery (553) or 
radiotherapy (545). With a median follow up of 10 years, there were 17 deaths from PCa, 
8 in the active monitoring group, 5 in the surgery group and 4 in the radiotherapy group. 
Surgery and radiotherapy were associated with lower incidence of disease progression 
(112 in active surveillance [AS] group, 46 in RP group and 46 in RT group, p<0.001) and 
metastases (33 in AS group, 13 in RP group and 16 in RT group, p=0.004) but 10-year 
cancer specific mortality was low irrespective of the management assigned with no 
differences observed among treatments (98.8% in all groups, p=0.5). Consequently, they 
estimated 27 men would need to be treated with prostatectomy or 33 men with 
radiotherapy rather than receive active monitoring to avoid 1 patient having metastatic 
disease. A total of 9 men would need to be treated with RP or radiotherapy to avoid 1 
patient having clinical progression. Although most patients had tumors with a Gleason 
score of 6 (77%) or T1c stage disease (76%), data considering only low-risk PCa were 
not reported. PROTECT trial also investigated quality of life of 1,643 patients using 
validated questionnaires and patients treated with RP had the greatest negative effect on 
sexual function and urinary continence [26]. 
 
Pathological findings at radical prostatectomy in patients with low risk PCa 
Many studies have evaluated pathological findings at RP in patients with low-risk 
PCa (Table 3). Evaluating predictors of upstaging or upgrading are potentially helpful in 
identifying low-risk PCa patients who may benefit from early whole-gland treatment. Dinh 
et al.[27] analyzed data of 10,273 low-risk PCa patients who had RP in the SEER 
database. Upgrading and upstaging were identified in 44% and 9.7%, respectively. 
Similar findings have been observed in other retrospective studies [28],[29],[30],[31], 
suggesting risk of harboring pathological Gleason score >6 ranged from 30% to 55% and 
risk of pathological Gleason 8-10 disease was minimal (0.7% to 1.7%). Extraprostatic 
extension was reported in 9- 26% and positive surgical margin rate ranged from 11%-
16%. Lymph node metastases at final pathological report were exceedingly rare (range: 
0.6%-0.7%). Among men with very low-risk PCa, the risk of extraprostatic extension at 
RP is approximately 25%[32], while upgrading has been reported in approximately 33% 
[32],[33]. Although upstaging and upgrading rates were lower in very low-risk PCa when 
compared to low-risk PCa, the risk of harboring adverse pathologic features is still 
considerable.   
Weiner et al.[29] evaluated the impact of delayed RP (untreated for a minimum 
of 6 months) in 17,943 low-risk PCa patients and found half of patients experienced at 
least one adverse pathologic outcome at RP specimen, although delaying RP up to 12 
months did not change the risk of adverse pathology. Auffenberg et al.[34] recently 
evaluated 2,858 low-risk PCa patients from practices in Michigan Urological Surgery 
Improvement Collaborative (MUSIC). Among the group, 778 (27%) underwent immediate 
RP while AS was the primary strategy for 1,359 (48%). Compared to those treated with 
immediate RP, men undergoing delayed surgery were more likely to have Gleason score 
7 or greater (69.2% vs. 48.8%, respectively: p=0.004). However, no difference was found 
considering positive margin rates, extraprostatic extension, seminal vesicle invasion or 
lymph node metastases[35].  
Predicting adverse pathologic features at RP in low-risk PCa patients might be 
of paramount importance for selecting appropriate AS candidates. However, it has to be 
highlighted that typically patients underwent RP after a single diagnostic biopsy. In 
contrast, patients included in AS protocols often undergo multiple staging biopsies and 
frequently MRI.   
 
Active surveillance 
AS is an attractive option for patients with low-risk PCa. Tosoian et al.[36] reported 
data of 1,298 very-low and low-risk PCa patients enrolled in an active surveillance 
protocol between 1995 and 2014. The surveillance protocol included semiannual PSA 
and digital rectal examinations with an annual 12-14 core biopsy for most men. Curative 
intervention was recommended for disease reclassification, defined as biopsy findings no 
longer meeting the inclusion criteria. The median treatment-free survival (TFS) rate was 
8.5 years and cumulative incidence of TFS was 50% and 43% at 10 and 15 years. 
Cancer-specific survival at 10 and 15 years were both 99.9%. The excellent long-term 
results reflect the strict inclusion criteria, rigorous follow-up, and low threshold for 
recommending treatment.   
Godtman et al.[37] updated the experience of the Göteborg screening trial 
(ISRCTN54449243) which enrolled very low, low and intermediate risk PCa patients 
between 1995 and 2014 to AS. Patients had PSA every 3-12 months and biopsy in cases 
of progression (defined as PSA and/or T-stage progression) or every 2-3 years in men 
with stable disease. For men with very low-risk cancer, 15-year cancer-specific survival 
was 100% but decreased to 94% for men with low-risk PCa. 
The Prostate Cancer Research International Active Surveillance (PRIAS) [38]  
group recently reported the largest known AS experience. The original inclusion criteria 
were: Gleason ≤6, clinical stage ≤cT2c, PSA ≤10 ng/ml, two or fewer cores positive for 
PCa, PSA density ≤0.2 ng/ml per cubic centimeter, and fitness for curative treatment. 
Inclusion criteria and follow-up schemes were modified over the study period. Changes 
regarded the inclusion of patients with minimal Gleason 3+4 (≤10% tumor involvement 
per biopsy core, maximum 2 cores positive) if age ≥70 yr. Follow up strategy required a 
PSA test every 3 months and a digital rectal examination every 6 months for the first 2 
years. Thereafter, PSA was done every 6 months and digital rectal examination yearly. 
Repeat biopsies were scheduled at 1, 4, 7 and 10 years after diagnosis. Follow up and 
criteria to switch to active treatment also changed during the study period. Through 2014 
they were: Gleason ≥7, more than two positive cores, stage > cT2 or PSA-DT < 3 yr (if at 
least four PSA values are available). Subsequently, these criteria were changed because 
of the high number of patients dropped from AS and concerns for high rates of 
unnecessary treatment[39]. Specifically, a PSA DT <3 years is no longer used to switch 
to active treatment.  Also, the presence of two positive cores triggers an MRI with targeted 
biopsy but not by itself a switch to active treatment. The original criteria explain the low 
TFS rates, with 48% and 27% at 5 and 10 yr, respectively. Rates of treatment and long-
term outcomes are entirely dependent on eligibility criteria, follow up strategies and 
thresholds for intervention (Table 4). Almost all series included in our manuscript evaluate 
TFS rate which consist in the number of patients still on AS after a certain period. The 
decision to submit patients to whole-gland treatment rather than continue with AS is 
mainly related to the reclassification of the tumor with an increased risk of progression. 
Almost 2 out 3 patients are still in AS after 5 year of follow up, although in some series 
these percentages drop to 50%. Long term follow up is provided by some series which 
indicate a 15 yr TFS ranging from 34% to 55%. Low-risk patients on AS record excellent 
long-term survival outcomes with 10-year cancer-specific survival ranging from 98.1% to 
100%. These data suggest that even in stringent schemes, there are limited number of 
patients who died from PCa. Based on these data, AS should be discussed as a 
management option for any man with very low-risk or low-risk PCa. Welty et al.[40] 
defined factors associated with progression in patients enrolled to AS. They found PSA 
density, number of biopsies and time between biopsies were significantly associated with 
biopsy reclassification or local treatment.  
Current European guidelines[8] recommend AS with a level of evidence of 2a for 
patients with low risk PCa and >10 years of life expectancy. Current NCCN guidelines 
[12] distinguished very low risk and low risk PCa. Very low-risk PCa should be considered 
to AS when their life expectancy is between 10 and 20 years. In contrast, when life 
expectancy is less than 10 years, observation is recommended. For low risk PCa patients, 
AS is an option along with EBRT, brachytherapy and RP for patients with more than 10 
year of estimated life expectancy. Patients with less than 10 year of expected survival 
should be observed only.  
 
Focal therapy for low risk PCa 
Focal therapy may represent a viable option for men with low or intermediate-risk 
PCa[41]. The main purpose of focal therapy is to selectively ablate tumors while 
attempting to limit toxicity by sparing the neurovascular bundles, sphincter and urethra. 
In this regard, low volume unifocal or unilateral tumors represent the ideal target for this 
approach although at the time no high quality long-term data exist supporting this theory 
and therefore should be offered very cautiously[42],[43]. Several types of ablative 
technologies are available: high-intensity focused ultrasound (HIFU), cryotherapy, 
photodynamic therapy (PDT), laser interstitial thermotherapy (LITT), electroporation, 
radiation frequency ablation and focal brachytherapy[44],[45]. At this time, focal therapy 
should be considered an experimental approach that might potentially reduce toxicity 
compared to whole-gland treatment. High quality prospective trials are required to 
demonstrate oncologic or quality-of-life benefits over other available options[8]. A 
selection of studies reporting oncological outcomes in low-risk PCa patients treated with 
focal therapy is presented in Table 5.  
Several studies reported excellent outcomes for low risk PCa patients treated with 
HIFU. Feijoo et al. [46] recently reported data of 67 patients with low-risk PCa treated with 
HIFU where 75% had a negative biopsy at 6 months after treatment. Complications were 
reported in a small portion of men (8% Clavien-Dindo grade 2 and 2.8% grade 3) and full 
continence was achieved in all patients. Potency (defined as IIEF score ≥22) was 
maintained in 11 of 21 patients. These findings confirm previous data of Ahmed et al. 
which[47] reported similar results in 41 PCa patients (11 low risk PCa). Excellent 
functional outcomes were reported while 77% of patients were free of tumor at 6-month 
biopsy. In general, the quality of evidence is poor and further data are required. 
Current guidelines recommend cryotherapy as an option in organ confined PCa 
and with minimal tumor extension [48],[49],[50]. The usage of focal cryoablation is 
increasing over whole gland-cryoablation as oncological outcomes appear similar (in 
select patients) with lower rates of urinary, sexual or bowel dysfunction[51]. Negative 
follow-up prostate biopsy was reported in 55%-86% of patients. Considering functional 
outcomes, complete continence was in 98.4% - 100%. However, the use of different 
definitions of potency and the lack of preoperative functional data makes it difficult to fully 
evaluate this outcome. In the largest study [47] evaluating erectile function after 
cryoablation, maintenance of spontaneous erection was reported in 58% of patients. 
Donnelly et al. [52],[53] reported the only randomized control trial comparing focal 
versus whole-gland therapy: cryosurgery vs EBRT. Overall, 244 patients with localized 
PCa were randomized, but of these only 20 had low-risk characteristics (10 treated with 
cryosurgery and 10 with EBRT). With a median follow up of 100 months, 3-year disease 
progression was observed in 23.9% and 23.7% of patients treated with cryoablation and 
EBRT, respectively. However, no analyses were done considering low risk PCa only.  
These results were confirmed in a recent meta-analysis where data from 3,995 
patients across 19 studies compared cryotherapy vs. RP vs. EBRT[54]. There was no 
evidence that mortality (4-year survival was 93% for cryotherapy and 91% for EBRT) or 
other specific outcomes were different between cryotherapy and EBRT. However, all the 
studies included were considered at high risk of selection bias. Considering functional 
outcomes, urinary incontinence at 1 year was lower for cryosurgery than for RP. 
Considering overall complications, no significant difference was reported, however 
patients treated with cryosurgery or EBRT had lower rates of urethral stricture than 
patients treated with RP.  
 
Standard diagnosis and implications for research in low risk PCa 
The classification of localized PCa into low, intermediate and high risk groups has 
provided a useful system for reporting outcomes and to guide physicians in selecting 
patients who might benefit from whole-gland treatments. However, even the low-risk PCa 
category is a heterogeneous group with an outcome not invariably favorable. For 
instance, a high proportion of patients clinically defined as low risk may harbor adverse 
pathologic features at RP. Strategies exist to minimize over detection of low risk PCa. 
According to current guidelines, prostate biopsy should be offered to patients with a 
concerning digital rectal examination or elevated PSA [41]. PSA is organ-specific but not 
cancer-specific and therefore higher levels may be dependent on benign conditions and 
the  risk of having a Gleason ≥7 is not zero even in patients with low PSA ranging between 
0.8% to 6.7%[55]. PSA should be always repeated before having a prostate biopsy. 
Moreover, its value should be considered in context of the age and health of an individual 
man. Life expectancy must be considered as a fundamental part of the decision making 
in low risk PCa where local treatment is not associated with improvement in survival. 
However, these parameters are not entirely sufficient and there is a potential need for 
biomarkers to individualize the risk of harboring a clinical significant PCa. Ideally, these 
markers should be able to differentiate the majority of patients with truly indolent disease, 
suitable for observation only, from the minority with significant PCa that may benefit from 
early treatment.  
 
Biomarkers 
PSA isoforms may help to identify patients at increased risk of harboring adverse 
pathologic features at biopsy. Tosoian et al.[56] used PSA isoforms in a cohort of 167 
patients enrolled in AS program to predict unfavorable findings on annual biopsy. [-
2]proPSA and prostate health index (PHI) provided the greatest predictive accuracy for 
high grade cancer. Similar findings have been observed by other authors[57],[58],[59]. 
Several studies indicate that fPSA and PSA isoforms may be helpful in predicting adverse 
pathologic features, however the overlap between favorable and unfavorable groups 
makes it difficult to currently include these parameters in preoperative predictive 
models[60]. A four kallikrein (4k) panel has been used[61] to investigate the presence of 
high grade cancer in men on AS. Plasma was collected before the first and subsequent 
AS biopsies in 718 men enrolled in the prospective Canary PASS trial. The use of 4K 
improved AUC from 0.74 to 0.78 in predicting reclassification at first AS biopsy (defined 
as Gleason ≥7). The test however, showed no benefit for the prediction of reclassification 
at subsequent biopsies.  
Urinary markers have also shown promising results in predicting adverse 
pathologic features. Prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG are 
commercially available. PCA3 is a prostate-specific gene expressed in 95% of PCa and 
overexpressed in cancer tissue[62]. PCA3 levels are independent of prostate volume and 
PSA, but may be higher with more aggressive tumors[63]. A recent meta-analysis 
included 11 studies and found PCA3 can help to select patients at increased risk of an 
aggressive cancer even after a prior negative prostate biopsy[64]. PCA3 has been also 
combined with clinical data to improve selection of patients at higher risk of harboring 
aggressive cancers[65]. TMPRSS2:ERG has been used in combination with PCA3; 
TMPRSS2:ERG has high specificity while PCA3 has high sensitivity for PCa. A 
combination of PCA3 and TMPRSS2:ERG (MiPS: Michigan Prostate Score) has been 
validated by Tomlins et al.[66] who found this novel tool outperforms standard clinical 
criteria for predicting PCa and high-grade PCa on biopsy. Specifically, they evaluated 
1244 men presenting for biopsy, and found that models incorporating T2:ERG had greater 
AUC than PSA for predicting PCa or high grade PCa on biopsy. Interestingly, the utility 
of both urine TMPRSS2:ERG and PCA3 was described for men on active 
surveillance[67]. The findings by Lin et al.[67] therefore suggest these biomarkers could 
be used to find aggressive PCa in low risk PCa patients, however the biomarkers were 
not independently significant upon multivariable analyses.  
Several histopathologic biomarkers have showed promising results in the 
prediction of aggressiveness of PCa after being diagnosed at biopsy. Ki-67 is a nuclear 
protein associated with ribosomal RNA synthesis that is typically measured by 
immunohistochemistry to assay cell proliferation. Its prognostic values has been shown 
many times[68],[69],[70] and should be considered by physicians for men with low risk 
PCa. PTEN loss has a well-established role in PCa. and has been related to a less 
favorable prognosis[71]. Murphy et al.[72] described PTEN loss is infrequent in clinically 
insignificant PCa and therefore when present a higher-grade tumor should be 
suspected[73,74].  However, at this time, none of the above histological tests are in 
routine clinical use.  
Commercially available tissue-based prognostic panels do exist [75], however only 
OncotypeDX® and Prolaris® have been validated on men with low risk PCa. 
OncotypeDX® is a test developed by Genomic Health (Redwood City, California) 
following PCa diagnosis. This tool is a quantitative RT-PCR assay performed on FFPE 
tissue from needle biopsies incorporating 12 cancer related genes representing four 
biological pathways (stromal response; androgen signaling; proliferation; cellular 
organization) and 5 reference genes which are algorithmically combined to calculate the 
Genomic Prostate Score (GPS) [76]. The derived GPS ranges from 0 to 100 with the 
higher the number correlating with a higher probability of harboring adverse pathology 
(primary Gleason 4 or ECE) at RP in men diagnosed with low or low-intermediate risks 
prostate cancer at prostate biopsy. Cullet et al.[77] described 431 patients with very low, 
low, and intermediate risk-stratified PCa at biopsy, and demonstrated the ability of 
OncotypeDX® to provide independently significant value in predicting adverse pathology 
at RP and BCR.  
Prolaris® is a prognostic test developed by Myriad Genetics (Wakara Way, Salt 
Lake City, UT) and used on biopsies from low and very low-risk patients. This test is 
based on the expression of 31 cell cycle progression and 15 housekeeping genes and is 
an extension of their breast cancer test. The result is represented by a proliferative index, 
expressed as a cell cycle progression (CCP) score[78]. Bishoff et al. [79] analyzed 582 
patients from the Martini Clinic (n=283), Durham Veterans Affairs Medical Center (n=176) 
and Intermountain Healthcare (n=123), and showed an association of the biopsy CCP 
score with adverse outcomes after surgery. Cuzick et al.[78] in a larger study evaluated 
the CCP score and its ability of predicting BCR in a U.S. cohort of RP patients and 
mortality in a U.K. cohort of patients predominantly diagnosed via TURP. Additionally, the 
CCP  was validated by Freedland et al. [80] in primary external radiation treated patients. 
Cooperberg et al. [81] analyzed 413 RP patients and reported a combined CCP and 
CAPRA-S score for the overall cohort and the low-risk subset more accurately predicted 
BCR compared to either alone.  
 
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) traditionally has been used following 
prostatic biopsy for staging. However, there is an emerging data suggesting its role in 
patient selection for, and monitoring during, active surveillance. Multiparametric magnetic 
resonance imaging (mpMRI) is a combination of anatomical imaging using T1-weighted 
(T1W) and T2-weighted (T2W) sequences with one or more functional imaging methods. 
The combination of anatomic and functional MRI has been shown to improve the 
detection of PCa[82].   
Considering low risk PCa, several studies analyzed patients (potentially eligible for 
AS protocols) treated with RP and preoperatively investigated with 
MRI[83],[84],[85],[86],[87],[88]. Unfortunately, different definitions of unfavorable 
pathology, biopsy schemes and inclusion criteria were used. Ploussard et al.[86] failed to 
assess any improved prediction of high risk and/or non-organ confined disease in RP for 
those patients selected for AS based on an extended 21-core biopsy scheme and 
stringent AS criteria. However, other findings support the use of mpMRI in the accrual of 
patients for AS. In this setting, Turkbey et al.[85] analyzed preoperative data of 133 
patients staged with mpMRI. Lesions were identified in mpMRI for 126 patients with a 
sensitivity of 93%. In context, a misclassification occurred in 16 patients and with use of 
mpMRI could be avoided in 12 of these. The impact of MRI in low and intermediate risk 
PCa candidates for AS has been evaluated recently in a meta-analyses by Schoots et 
al[89], who found that a suspicious lesion at MRI for PCa was found in two-thirds of men 
otherwise suitable for AS. MRI therefore helps in determining clinically significant disease 
at repeat biopsy especially when biopsies are targeted to suspicious MRI lesions. Finally, 
a positive MRI is more likeably to be associated with upgrading at RP (Gleason score >6) 
than a negative MRI (43% vs. 27%). Consequently, the PRECISE recommendations 
suggested indications of MRI for men on AS [90]. Experts developed a checklist of items 
for reporting MRI and key recommendations include reporting the index lesion size and 
the change over time on a 1-5 scale. The PRECISE recommendations might be helpful 
for physicians to facilitate data collection and distinguish measurement error and natural 
variability in MRI from true radiologic progression in PCa patients in AS schemes. 
Similarly, MRI fusion biopsy may play a role in low risk PCa patients. Tran et al.[91] 
examined the role of MRI fusion biopsy for men with low risk PCa managed with AS, 
finding that some lesions observed with MRI fusion were missed with the standard 
systematic sampling. In contrast, upgrading also occurred in areas outside targeted 
biopsy, suggesting the need of systematic sampling even in the context of MRI fusion 
biopsy. These results confirm previous findings on this topic[92],[93],[94],[95].   
 
Conclusion 
The incidence of low risk PCa has increased as a consequence of PSA-based 
screening. High quality prospective trials have not shown a definitive survival benefit for 
whole-gland treatments compared to observation. Long-term active surveillance has 
shown encouraging results, while more robust data are required to understand the 
potential role of focal therapy. Tissue biomarkers and MRI may improve risk stratification 
of low risk PCa to identify the proportion of men who might benefit from early treatment. 
  
Figures 
Figure 1- Flow diagram of evidence acquisition in a systematic review for patients affected 
by low risk prostate cancer.  
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